BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

119 related articles for article (PubMed ID: 38600673)

  • 1. Role of adjuvant therapy in resected periampullary adenocarcinoma: A propensity matched case-control study.
    Srivastava A; Nekarakanti PK; Kanchodu S; Srivastava S; Mishra PK; Saluja SS
    Ann Hepatobiliary Pancreat Surg; 2024 Apr; ():. PubMed ID: 38600673
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Adjuvant Chemotherapy for Resected Ampulla of Vater Carcinoma: Retrospective Analysis of 646 Patients.
    Kim JH; Jeong JH; Ryoo BY; Kim KP; Chang HM; Oh D; Song TJ; Lee SS; Seo DW; Lee SK; Kim MH; Park Y; Kwon JW; Hwang DW; Lee JH; Lee W; Kim SC; Yoo C; Song KB
    Cancer Res Treat; 2021 Apr; 53(2):424-435. PubMed ID: 33171024
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Adjuvant chemotherapy versus chemoradiotherapy in the management of patients with surgically resected duodenal adenocarcinoma: A propensity score-matched analysis of a nationwide clinical oncology database.
    Ecker BL; McMillan MT; Datta J; Lee MK; Karakousis GC; Vollmer CM; Drebin JA; Fraker DL; Roses RE
    Cancer; 2017 May; 123(6):967-976. PubMed ID: 28263387
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Adjuvant Chemotherapy and Effect on Long-Term Survival in Ampullary Adenocarcinoma: A Multicenter Cohort Study.
    Shin DW; Lee JM; Lee JC; Lee HS; Yoon SB; Jang DK; Park JK; Jung MK; Lee YS; Hwang JH
    J Am Coll Surg; 2023 Sep; 237(3):501-512. PubMed ID: 37222437
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Adjuvant immunotherapy improves recurrence-free and overall survival following surgical resection for intermediate/advanced hepatocellular carcinoma
    Xu X; Wang MD; Xu JH; Fan ZQ; Diao YK; Chen Z; Jia HD; Liu FB; Zeng YY; Wang XM; Wu H; Qiu W; Li C; Pawlik TM; Lau WY; Shen F; Lv GY; Yang T
    Front Immunol; 2023; 14():1322233. PubMed ID: 38268916
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The Efficacy of S-1 as Adjuvant Chemotherapy for Resected Biliary Tract Carcinoma: A Propensity Score-Matching Analysis.
    Miyata Y; Kogure R; Nakazawa A; Nagata R; Mitsui T; Ninomiya R; Komagome M; Maki A; Kawarabayashi N; Beck Y
    J Clin Med; 2021 Mar; 10(5):. PubMed ID: 33804297
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Propensity-Score Matched Analysis of Survival Outcomes of Adjuvant Therapy in Stage II-III Signet-Ring Cell Carcinoma of the Colon.
    Emile SH; Horesh N; Garoufalia Z; Gefen R; Strassmann V; Wexner SD
    Clin Colorectal Cancer; 2024 Mar; 23(1):35-45. PubMed ID: 37980215
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Adjuvant chemotherapy for resected duodenal adenocarcinoma: a case-matched analysis in nation wide cohort.
    de Bakker JK; Meijer LL; Zonderhuis BM; van der Vliet HJ; Daams F; van Grieken NCT; Lissenberg-Witte BI; Kazemier G
    Acta Chir Belg; 2023 Oct; 123(5):502-508. PubMed ID: 35727126
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Impact of adjuvant chemotherapy on prognosis in intrahepatic cholangiocarcinoma patients underwent radical resection].
    Su JB; Zhang JW; Chen C; Qiu YH; Wu H; Song TQ; He Y; Mao XH; Zhai WL; Cheng ZJ; Li JD; Si SB; Cai ZQ; Geng ZM; Tang Z
    Zhonghua Wai Ke Za Zhi; 2022 Apr; 60(4):356-362. PubMed ID: 35272427
    [No Abstract]   [Full Text] [Related]  

  • 10. Intensified adjuvant therapy for pancreatic and periampullary adenocarcinoma: survival results and observations regarding patterns of failure, radiotherapy dose and CA19-9 levels.
    Abrams RA; Grochow LB; Chakravarthy A; Sohn TA; Zahurak ML; Haulk TL; Ord S; Hruban RH; Lillemoe KD; Pitt HA; Cameron JL; Yeo CJ
    Int J Radiat Oncol Biol Phys; 1999 Jul; 44(5):1039-46. PubMed ID: 10421536
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Evaluation of Prognostic Factors and Adjuvant Chemotherapy in Patients With Small Bowel Adenocarcinoma Who Underwent Curative Resection.
    Aydin D; Sendur MA; Kefeli U; Unal OU; Tastekin D; Akyol M; Tanrikulu E; Ciltas A; Ustaalioglu BB; Uysal M; Esbag O; Yazilitas D; Tanrıverdi O; Bilici A; Arpaci E; Berk V; Yetisyigit T; Ozdemir NY; Oztop I; Alacacioglu A; Aydin O; Ozcelik M; Yildirim E; Dinc N; Gumus M
    Clin Colorectal Cancer; 2017 Sep; 16(3):220-227. PubMed ID: 27670893
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Propensity-matched analysis of adjuvant chemotherapy for completely resected Stage IB non-small-cell lung cancer patients.
    Li X; Zhang C; Sun Z; Yang F; Xiao R; Sui X; Jiang G; Zhong W; Wang J
    Lung Cancer; 2019 Jul; 133():75-82. PubMed ID: 31200832
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Association of Timing of Adjuvant Therapy With Survival in Patients With Resected Stage I to II Pancreatic Cancer.
    Ma SJ; Oladeru OT; Miccio JA; Iovoli AJ; Hermann GM; Singh AK
    JAMA Netw Open; 2019 Aug; 2(8):e199126. PubMed ID: 31411712
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Surgery Versus Chemotherapy and Radiotherapy For Early and Locally Advanced Small Cell Lung Cancer: A Propensity-Matched Analysis of Survival.
    Wakeam E; Acuna SA; Leighl NB; Giuliani ME; Finlayson SRG; Varghese TK; Darling GE
    Lung Cancer; 2017 Jul; 109():78-88. PubMed ID: 28577955
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [A multi-center retrospective study of perioperative chemotherapy for gastric cancer based on real-world data].
    Ding XW; Zheng ZC; Zhao Q; Zhai G; Liang H; Wu X; Zhu ZG; Wang HJ; He QS; He XL; Du YA; Chen LC; Hua YW; Huang CM; Xue YW; Zhou Y; Zhou YB; Wu D; Fang XD; Dai YG; Zhang HW; Cao JQ; Li LP; Chai J; Tao KX; Li GL; Jie ZG; Ge J; Xu ZF; Zhang WB; Li QY; Zhao P; Ma ZQ; Yan ZL; Zheng GL; Yan Y; Tang XL; Zhou X
    Zhonghua Wei Chang Wai Ke Za Zhi; 2021 May; 24(5):403-412. PubMed ID: 34000769
    [No Abstract]   [Full Text] [Related]  

  • 16. Gemcitabine-based adjuvant chemotherapy in subtypes of ampullary adenocarcinoma: international propensity score-matched cohort study.
    Moekotte AL; Malleo G; van Roessel S; Bonds M; Halimi A; Zarantonello L; Napoli N; Dreyer SB; Wellner UF; Bolm L; Mavroeidis VK; Robinson S; Khalil K; Ferraro D; Mortimer MC; Harris S; Al-Sarireh B; Fusai GK; Roberts KJ; Fontana M; White SA; Soonawalla Z; Jamieson NB; Boggi U; Alseidi A; Shablak A; Wilmink JW; Primrose JN; Salvia R; Bassi C; Besselink MG; Abu Hilal M
    Br J Surg; 2020 Aug; 107(9):1171-1182. PubMed ID: 32259295
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Intensified adjuvant combined modality therapy for resected periampullary adenocarcinoma: acceptable toxicity and suggestion of improved 1-year disease-free survival.
    Chakravarthy A; Abrams RA; Yeo CJ; Korman LT; Donehower RC; Hruban RH; Zahurek ML; Grochow LB; O'Reilly S; Hurwitz H; Jaffee EM; Lillemoe KD; Cameron JL
    Int J Radiat Oncol Biol Phys; 2000 Nov; 48(4):1089-96. PubMed ID: 11072167
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effect of adjuvant chemotherapy with fluorouracil plus folinic acid or gemcitabine vs observation on survival in patients with resected periampullary adenocarcinoma: the ESPAC-3 periampullary cancer randomized trial.
    Neoptolemos JP; Moore MJ; Cox TF; Valle JW; Palmer DH; McDonald AC; Carter R; Tebbutt NC; Dervenis C; Smith D; Glimelius B; Charnley RM; Lacaine F; Scarfe AG; Middleton MR; Anthoney A; Ghaneh P; Halloran CM; Lerch MM; Oláh A; Rawcliffe CL; Verbeke CS; Campbell F; Büchler MW;
    JAMA; 2012 Jul; 308(2):147-56. PubMed ID: 22782416
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Propensity score-matched analysis of adjuvant chemotherapy for stage I non-small cell lung cancer.
    Tsutani Y; Miyata Y; Kushitani K; Takeshima Y; Yoshimura M; Okada M
    J Thorac Cardiovasc Surg; 2014 Oct; 148(4):1179-85. PubMed ID: 25112928
    [TBL] [Abstract][Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.